Biogen (BIIB) Tops Q2 EPS by 53c; CEO Scangos to Step Down
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
July 21, 2016 7:00 AM EDTSecond quarter 2016 GAAP diluted EPS rise 22%; Non-GAAP diluted EPS rise 23%
Company raises financial guidance for the year and authorizes $5 billion share repurchase program
George A. Scangos, Ph.D., to step down as CEO
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2016 financial results, including:
Total revenues of $2.9 billion, a 12% increase versus the same period in the prior year. Growth was driven by increases in worldwide revenues from the Companys multiple sclerosis (MS) and hemophilia... More